Response of rat ventral prostate to a new and novel 5 alpha-reductase inhibitor.
D058891:5-alpha Reductase Inhibitors; D000375:Aging; D000728:Androgens / Q000494:pharmacology; D000818:Animals; D001378:Azasteroids / Q000494:pharmacology*; D002369:Castration; D013196:Dihydrotestosterone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D005485:Flutamide / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011374:Progesterone / Q000494:pharmacology; D011467:Prostate / Q000187:drug effects / Q000254:growth & development / Q000502:physiology*; D051381:Rats; D012669:Seminal Vesicles / Q000187:drug effects; D013260:Steroids, Heterocyclic / Q000494:pharmacology*; D013739:Testosterone / Q000378:metabolism
D058891:5-alpha Reductase Inhibitors; D000728:Androgens; D001378:Azasteroids; D013260:Steroids, Heterocyclic; D013196:Dihydrotestosterone; D013739:Testosterone; D011374:Progesterone; C031563:17-N,N-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one; D005485:Flutamide; D010088:Oxidoreductases